Rituximab-ameliorated Cutaneous Extravascular Necrotizing Granuloma

Naoya Oka^{1

2}, Yusuke Yoshida¹, Manami Sueoka^{3

4}, Shintaro Hirata¹

Affiliations

¹ Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Japan.
² Department of Rheumatology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan.
³ Department of Dermatology, Hiroshima University Hospital, Japan.
⁴ Department of Dermatology, Hiroshima-Nishi Medical Center, Japan.

Case Reports

Naoya Oka et al. Intern Med. 2024.

. 2024 May 1;63(9):1333-1334.

doi: 10.2169/internalmedicine.2313-23. Epub 2023 Sep 1.

Naoya Oka^{1

2}, Yusuke Yoshida¹, Manami Sueoka^{3

4}, Shintaro Hirata¹

¹ Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Japan.
² Department of Rheumatology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan.
³ Department of Dermatology, Hiroshima University Hospital, Japan.
⁴ Department of Dermatology, Hiroshima-Nishi Medical Center, Japan.

No abstract available

Keywords: ANCA; granuloma; mepolizumab; rituximab.

Figures

1. Tanomogi N, Kubota M, Kato M. Extravascular necrotizing granuloma: a diagnostic clue for eosinophilic granulomatosis with polyangiitis. J Rheumatol 49: 1395, 2022. - PubMed
1. Newell EL, Mallipeddi R, Murdoch ME, Groves R, Black MM, Robson A. A case of cutaneous extravascular necrotizing granuloma without systemic manifestations. Clin Exp Dermatol 32: 509-512, 2007. - PubMed